Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Mario Cozzolino, Andrea Galassi, Ferruccio Conte, Michela Mangano, Luca Di Lullo & Antonio Bellasi. (2017) Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide. Therapeutics and Clinical Risk Management 13, pages 679-689.
Read now
Read now
J. Bover, P. Ureña-Torres, M. J. Lloret, C. Ruiz, I. DaSilva, M. M. Diaz-Encarnacion, C. Mercado, S. Mateu, E. Fernández & J. Ballarin. (2016) Integral pharmacological management of bone mineral disorders in chronic kidney disease (part II): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification. Expert Opinion on Pharmacotherapy 17:10, pages 1363-1373.
Read now
Read now
J. Bover, P. Ureña-Torres, M. J. Lloret, C. Ruiz-García, I. DaSilva, M. M. Diaz-Encarnacion, C. Mercado, S. Mateu, E. Fernández & J. Ballarin. (2016) Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification. Expert Opinion on Pharmacotherapy 17:9, pages 1247-1258.
Read now
Read now
Articles from other publishers (20)
Bohou Li, Xueqin Chen, Juan Hu, Guibao Ke, Nan Jiang, Fengxia Zhang, Zhiwen Lian, Sichun Wen, Qiong Wu, Yubin Xia, Hong Zhang, Sujuan Kuang, Lixia Xu, Chunyu Deng & Shuangxin Liu. (2023) COMMD5 is involved in the mechanisms of hypotension after parathyroidectomy in patients receiving hemodialysis. European Journal of Pharmacology 944, pages 175596.
Crossref
Crossref
Takashi Shigematsu, Shinji Asada, Yuichi Endo, Takehisa Kawata, Masafumi Fukagawa & Tadao Akizawa. (2022) Evocalcet with vitamin D receptor activator treatment for secondary hyperparathyroidism. PLOS ONE 17:2, pages e0262829.
Crossref
Crossref
Nikolaos Sabanis, Eleni Paschou, Aikaterini Drylli, Panagiota Papanikolaou & Georgios Zagkotsis. (2022) Uremic Leontiasis Ossea: Theoretical Concepts and Practical Considerations. Saudi Journal of Kidney Diseases and Transplantation 33:5, pages 702-715.
Crossref
Crossref
Enrique Alonso-Perez, Carles Forné, Marco Soro, Marta Valls, Anton-Giulio Manganelli & Jose M. Valdivielso. (2021) Health Care Costs in Patients with and without Secondary Hyperparathyroidism in Spain. Advances in Therapy 38:10, pages 5333-5344.
Crossref
Crossref
Zhuolin Zhang, Lele Cai, Hong Wu, Xinglu Xu, Wenqing Fang, Xuan He, Xiao Wang & Xin Li. (2021) Paricalcitol versus Calcitriol + Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease in China: A Cost-Effectiveness Analysis. Frontiers in Public Health 9.
Crossref
Crossref
Antonio Bellasi, Mario Cozzolino, Fabio Malberti, Giovanni Cancarini, Ciro Esposito, Carlo Maria Guastoni, Patrizia Ondei, Giuseppe Pontoriero, Ugo Teatini, Giuseppe Vezzoli, Marzia Pasquali, Piergiorgio Messa & Francesco Locatelli. (2019) New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of working group on CKD-MBD of the Italian Society of Nephrology. Journal of Nephrology 33:2, pages 211-221.
Crossref
Crossref
Zixing Ma, Tengfei Yu, Yan Wu, Dandan Liu, Xiaofei Zhang, Xin Miao, Haiyan Xing & Gang Li. (2019) Nano-lanthanum hydroxide, a novel phosphate binder, for treating hyperphosphatemia: A preclinical study. Biomedicine & Pharmacotherapy 111, pages 909-916.
Crossref
Crossref
Stuart M. Sprague. 2019. Endocrine Disorders in Kidney Disease. Endocrine Disorders in Kidney Disease
231
242
.
Julia Spoendlin, Sebastian Schneeweiss, Theodore Tsacogianis, Julie M. Paik, Michael A. Fischer, Seoyoung C. Kim & Rishi J. Desai. (2018) Association of Medicare's Bundled Payment Reform With Changes in Use of Vitamin D Among Patients Receiving Maintenance Hemodialysis: An Interrupted Time-Series Analysis. American Journal of Kidney Diseases 72:2, pages 178-187.
Crossref
Crossref
Antonio Bellasi, Luigi Morrone, Maria Cristina Mereu, Carlo Massimetti, Elena Pelizzaro, Giuseppe Cianciolo, Marzia Pasquali & Vincenzo Panuccio. (2018) CKD-MBD management: what is the role of parathyroidectomy? Results from a nationwide survey in Italy. Journal of Nephrology 31:4, pages 585-591.
Crossref
Crossref
Jiaoyan Zhao & Xuefeng Jiang. (2018) The application of sulfur-containing peptides in drug discovery. Chinese Chemical Letters 29:7, pages 1079-1087.
Crossref
Crossref
Svetla Staykova & Yana Bocheva. (2018) Tracing and comparing serum, specific, bone biomarkers in patients with secondary hyperparathyroidism. Scripta Scientifica Medica 50:2, pages 27.
Crossref
Crossref
Gian Paolo Rossi & Paul-Emmanuel Vanderriele. 2018. Disorders of Blood Pressure Regulation. Disorders of Blood Pressure Regulation
569
584
.
Heinz Weinberger. 2000. Ullmann's Encyclopedia of Industrial Chemistry. Ullmann's Encyclopedia of Industrial Chemistry
1
25
.
F. J. Mendoza, R. E. Toribio & A. Perez-Ecija. (2017) Nutritional secondary hyperparathyroidism in equids: Overview and new insights. Equine Veterinary Education 29:10, pages 558-563.
Crossref
Crossref
Raju Subramanian, Xiaochun Zhu, M. Benjamin Hock, Bethlyn J. Sloey, Benjamin Wu, Sarah F. Wilson, Ogo Egbuna, J. Greg Slatter, Jim Xiao & Gary L. Skiles. (2016) Pharmacokinetics, Biotransformation, and Excretion of [14C]Etelcalcetide (AMG 416) Following a Single Microtracer Intravenous Dose in Patients with Chronic Kidney Disease on Hemodialysis. Clinical Pharmacokinetics 56:2, pages 179-192.
Crossref
Crossref
Liviawati Wu, Murad Melhem, Raju Subramanian & Benjamin Wu. (2017) Drug disposition model of radiolabeled etelcalcetide in patients with chronic kidney disease and secondary hyperparathyroidism on hemodialysis. Journal of Pharmacokinetics and Pharmacodynamics 44:1, pages 43-53.
Crossref
Crossref
Hannah A. Blair. (2016) Etelcalcetide: First Global Approval. Drugs 76:18, pages 1787-1792.
Crossref
Crossref
R. Subramanian, X. Zhu, S. J. Kerr, J. D. Esmay, S. W. Louie, K. Z. Edson, S. Walter, M. Fitzsimmons, M. Wagner, M. Soto, R. Pham, S. F. Wilson & G. L. Skiles. (2016) Nonclinical Pharmacokinetics, Disposition, and Drug-Drug Interaction Potential of a Novel D-Amino Acid Peptide Agonist of the Calcium-Sensing Receptor AMG 416 (Etelcalcetide). Drug Metabolism and Disposition 44:8, pages 1319-1331.
Crossref
Crossref
Kai Duan, Karen Gomez Hernandez & Ozgur Mete. (2015) Clinicopathological correlates of hyperparathyroidism. Journal of Clinical Pathology 68:10, pages 771-787.
Crossref
Crossref